Last reviewed · How we verify
NCT06989307
COVID-19 Serologies Among Healthcare Workers at CHSD (SERO2)
trial in COVID-19 in 447 participants. Completed in 1 June 2021.
1 June 2021
Quick facts
| Lead sponsor | Centre Hospitalier de Saint-Denis |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 447 |
| Start date | 1 March 2021 |
| Primary completion | 1 June 2021 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across France |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- COVID-19 Serological Testing — all drugs for COVID-19 Serological Testing →
- COVID-19 Vaccines — all drugs for COVID-19 Vaccines →
- Health Personnel — all drugs for Health Personnel →
Sponsor
Centre Hospitalier de Saint-Denis
Who can join
Eligibility, any sex, with COVID-19 or COVID-19 Serological Testing. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study looks at how many healthcare workers at CHSD hospital developed antibodies against COVID-19 after the second and third waves of the pandemic and after receiving a vaccine. It aims to better understand who might still be at risk of infection, how long immunity lasts after getting COVID or the vaccine, and how reliable previous antibody tests were. Blood samples will be collected from volunteer hospital staff during a one-month period to measure their antibody levels and compare them to earlier results.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06989307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Centre Hospitalier de Saint-Denis trials
Trials by the same sponsor.
- NCT07204626 — Medical Anthropology and Migrants in Precarious Situations, Cared for in Intensive and Post-intensive Care Units · not yet recruiting
- NCT07206914 — Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital · not yet recruiting
- NCT07200999 — Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture · not yet recruiting
- NCT07170137 — Comparison of Uterine Distension in Hysterosonography Among Patients Monitored for Infertility · recruiting
- NCT07061561 — Objective Evaluation of Cough Effort in Tracheotomized Patients (LOST Study) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06989307 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Saint-Denis
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06989307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing